Mitsubishi UFJ Trust & Banking Corp lowered its stake in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 11.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 271,281 shares of the company's stock after selling 35,560 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.15% of Doximity worth $14,484,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently bought and sold shares of DOCS. FMR LLC lifted its position in shares of Doximity by 30.5% in the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company's stock valued at $297,920,000 after acquiring an additional 1,598,602 shares in the last quarter. Lord Abbett & CO. LLC purchased a new position in shares of Doximity during the third quarter valued at $29,453,000. Wilmington Savings Fund Society FSB acquired a new position in Doximity during the third quarter valued at $24,691,000. Vanguard Group Inc. lifted its stake in Doximity by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 11,203,569 shares of the company's stock worth $598,159,000 after acquiring an additional 485,102 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Doximity by 19.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company's stock worth $124,503,000 after acquiring an additional 472,565 shares during the period. Institutional investors and hedge funds own 87.19% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the stock. Mizuho boosted their price target on shares of Doximity from $55.00 to $65.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Leerink Partners raised Doximity from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $60.00 to $90.00 in a report on Friday, February 7th. Raymond James restated an "outperform" rating and issued a $83.00 price objective (up from $65.00) on shares of Doximity in a research note on Friday, February 7th. Piper Sandler upgraded shares of Doximity from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $31.00 to $78.00 in a report on Friday, February 7th. Finally, Bank of America upped their price target on shares of Doximity from $54.00 to $57.00 and gave the company a "neutral" rating in a report on Monday, January 6th. Eleven analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $64.22.
Get Our Latest Stock Analysis on Doximity
Insider Activity
In related news, Director Timothy S. Cabral sold 20,000 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the sale, the director now owns 6,360 shares of the company's stock, valued at $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 37.40% of the company's stock.
Doximity Trading Up 2.3 %
NASDAQ:DOCS traded up $1.30 during mid-day trading on Wednesday, hitting $58.02. The company's stock had a trading volume of 601,231 shares, compared to its average volume of 1,937,047. The company has a market capitalization of $10.83 billion, a price-to-earnings ratio of 58.06, a P/E/G ratio of 4.10 and a beta of 1.34. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $85.21. The stock has a fifty day moving average of $65.59 and a 200-day moving average of $54.81.
Doximity Company Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Recommended Stories

Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.